Jagannathan, P; Kakuru, A; Okiring, J; Muhindo, MK; Natureeba, P; Nakalembe, M; Opira, B; Olwoch, P; Nankya, F; Ssewanyana, I; +15 more... Tetteh, K; Drakeley, C; Beeson, J; Reiling, L; Clark, TD; Rodriguez-Barraquer, I; Greenhouse, B; Wallender, E; Aweka, F; Prahl, M; Charlebois, ED; Feeney, ME; Havlíř, DV; Kamya, MR; Dorsey, G; (2018) Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS medicine, 15 (7). e1002606. ISSN 1549-1277 DOI: https://doi.org/10.1371/journal.pmed.1002606

Downloaded from: http://researchonline.lshtm.ac.uk/4648586/

DOI: https://doi.org/10.1371/journal.pmed.1002606

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE

Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial

Prasanna Jagannathan1*, Abel Kakuru2, Jaffer Okiring2, Mary K. Muhindo3, Paul Natureeba2, Miriam Nakalembe3, Bishop Opira3, Peter Olwoch3, Felistas Nankya2, Isaac Ssewanyana2, Kevin Tetteh4, Chris Drakeley4, James Beeson5, Linda Reiling5, Tamara D. Clark6, Israel Rodriguez-Barraque6, Bryan Greenhouse6, Erika Wallender6, Francesca Aweeka7, Mary Prahl8, Edwin D. Charlebois9, Margaret E. Feeney6,8, Diane V. Havlir6, Moses R. Kamya2,10, Grant Dorsey6

1 Department of Medicine, Stanford University, Stanford, California, United States of America, 2 Infectious Diseases Research Collaboration, Kampala, Uganda, 3 Department of Obstetrics and Gynecology, Makerere University College of Health Sciences, Kampala, Uganda, 4 Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, United Kingdom, 5 Burnet Institute, Melbourne, Australia, 6 Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America, 7 Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, United States of America, 8 Department of Pediatrics, University of California, San Francisco, San Francisco, California, United States of America, 9 Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, California, United States of America, 10 Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda

* prasj@stanford.edu

Abstract

Background

Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) has been shown to reduce the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (IPTp-SP). However, limited data exist on how IPTp regimens impact malaria risk during infancy. We conducted a double-blinded randomized controlled trial (RCT) to test the hypothesis that children born to mothers given IPTp-DP would have a lower incidence of malaria during infancy compared to children born to mothers who received IPTp-SP.

Methods and findings

We compared malaria metrics among children in Tororo, Uganda, born to women randomized to IPTp-SP given every 8 weeks (SP8w, n = 100), IPTp-DP every 8 weeks (DP8w, n = 44), or IPTp-DP every 4 weeks (DP4w, n = 47). After birth, children were given chemoprevention with DP every 12 weeks from 8 weeks to 2 years of age. The primary outcome was incidence of malaria during the first 2 years of life. Secondary outcomes included time to malaria from birth and time to parasitemia following each dose of DP given during infancy. Results are reported after adjustment for clustering (twin gestation) and potential...
Impact of IPTp-DP on risk of malaria in early childhood

Why was this study done?
- Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) has been shown to reduce the burden of malaria during pregnancy compared to the current standard of care, sulfadoxine-pyrimethamine (SP).
• However, although there is some evidence that malaria in pregnancy may alter malaria susceptibility in infants, limited data exist on the impact of different IPTp regimens on malaria during early childhood.

• We hypothesized that children born to mothers who received IPTp with DP would have a lower incidence of malaria during the first 2 years of life compared to children born to mothers who received IPTp with SP.

**What did the researchers do and find?**

• We conducted a double-blinded randomized controlled trial between June 2014 and May 2017 comparing malaria metrics among 191 infants born to mothers randomized to receive IPTp with SP or IPTp with DP; children born to these mothers were given chemoprevention with DP every 12 weeks starting at 8 weeks of age and followed to 2 years of age.

• We found that children born to mothers given IPTp with DP did not have a lower incidence of malaria in infancy; in fact, children born to mothers who received IPTp with DP every 4 weeks in pregnancy had a significantly higher incidence of malaria and *Plasmodium falciparum* infection in infancy.

• We found that this increased incidence of malaria was only observed in female infants; furthermore, female children born to mothers who received IPTp with DP every 4 weeks in pregnancy had significantly lower piperaquine drug levels during infancy compared to male children.

**What do these findings mean?**

• Although IPTp with DP is more effective in preventing malaria in pregnancy compared to IPTp with SP, in this setting it was not associated with a lower risk of malaria in infancy.

• Although the results show an increased risk of malaria in female infants, these results should be interpreted with caution given the small sample size, especially when considering sex-stratified results.

• Future studies are needed both to confirm the impact of different IPTp regimens on malaria risk in infants, including those in settings where children are not given intermittent chemoprevention in infancy, as well as to understand the biologic mechanisms by which in utero drug exposure may lead to sex-specific changes in drug metabolism.

**Introduction**

Malaria during pregnancy remains a significant cause of morbidity and mortality in sub-Saharan Africa [1]. Although the majority of women living in endemic areas remain asymptomatic when infected with malaria parasites, these infections are associated with maternal anemia and adverse birth outcomes, including miscarriage, stillbirth, preterm birth, low birth weight (LBW), and infant mortality [2]. For pregnant women living in malaria-endemic areas, WHO
recommends the use of long-lasting insecticidal nets (LLINs) and intermittent preventive treatment of malaria during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) to prevent infection with malaria parasites and reduce the risk of adverse birth outcomes. However, there is concern for diminishing efficacy of these interventions because of the spread of vector resistance to the pyrethroid insecticides used in LLINs and widespread parasite resistance to SP [3,4]. Dihydroartemisinin-piperaquine (DP) has emerged as an attractive alternative to SP for IPTp, as it is highly efficacious and provides at least 4 weeks of posttreatment prophylaxis [5,6]. Recent randomized controlled trials (RCTs) from our group and others showed that, compared to IPTp-SP, IPTp-DP dramatically reduced risks of maternal parasitemia, symptomatic malaria, anemia, and placental malaria, and IPTp-DP was as safe and well tolerated as IPTp-SP [7,8]. However, there were minimal differences between the SP and DP groups in risks of adverse birth outcomes, including LBW and preterm birth. Furthermore, it remains unclear what impact these different IPTp regimens have on the risk of malaria during early childhood.

Several studies have reported associations between malaria in pregnancy and a child’s subsequent risk of malaria, with mixed findings. Many have reported that infants born to mothers with placental malaria [9–14] or peripheral parasitemia during pregnancy [15] have a significantly higher risk of malaria during infancy. However, one study found a lower risk of malaria in infancy among infants born to primigravid mothers with placental malaria than infants born to primigravid mothers without placental malaria [14], and others have reported no significant association between malaria in pregnancy and the risk of malaria in infancy [16–18]. Notably, all of these studies were observational and any associations observed were subject to confounding by shared levels of exposure to malaria-infected mosquitoes between mothers and their infants [16,19].

If malaria in pregnancy alters a child’s subsequent risk of malaria, one would hypothesize that maternal receipt of effective IPTp might alter this risk, although few studies have examined this question with rigorous randomized controlled studies. In an older, placebo-controlled trial of IPTp with mefloquine in Thailand, infants followed after birth whose mothers had either received mefloquine or placebo had similar risks of Plasmodium falciparum infection and symptomatic disease [20]. Three more recent IPTp trials in Africa comparing IPTp-SP + LLIN with LLIN alone [12], IPTp-SP with mefloquine [21], or IPTp-SP with intermittent screening and treatment (IST) with artemether-lumefantrine (AL) [18] also found that the incidence of malaria from birth to 12 months of age was not significantly different between groups of children. However, in each of these studies, the experimental IPTp group was not shown to significantly reduce the burden of placental malaria compared to controls [22–24].

We conducted a double-blinded RCT to evaluate the impact of different IPTp regimens on the risk of malaria in infancy. Pregnant women were randomized to receive IPTp with SP every 8 weeks (IPTp-SP8w), IPTp with DP every 8 weeks (IPTp-DP8wk), or IPTp with DP every 4 weeks (IPTp-DP4w). Children born to these mothers were given chemoprevention with DP every 12 weeks starting at 8 weeks of age and followed to 2 years of age. We tested the hypothesis that children born to mothers who received IPTp with DP would have a lower incidence of malaria during the first 2 years of life compared to children born to mothers who received IPTp with SP.

Methods

Ethics statement

The study was funded by the National Institutes of Health and approved by the Institutional Review Boards of the Makerere University School of Biomedical Sciences, the Uganda
National Council for Science and Technology, and the University of California, San Francisco. Written informed consent was obtained from all study participants.

**Study setting and participants**

The study was conducted in Tororo district, Uganda, from June 2014 through May 2017. Tororo district is an area of historically high malaria transmission intensity with perennial transmission and an estimated entomologic inoculation rate of 310 infectious bites per person-year in 2013 [25]. Following a universal LLIN campaign in November 2013, near universal LLIN coverage was reported in Tororo district, with minimal change in malaria metrics after LLIN distribution [26]. From December 2014 to February 2015, indoor residual spraying (IRS) using the carbamate bendiocarb was initiated in Tororo district for the first time and was associated with significant reductions in malaria transmission [26,27]; a second round of bendiocarb was conducted in June–July 2015, and a third round in November–December 2015. A fourth round of IRS was conducted in June–July 2016 with pyrimiphos-methyl (Actellic), a long-lasting organophosphate.

This study was divided into 2 phases, the first phase randomizing pregnant women to different IPTp regimens and the second phase—the focus of this analysis—following children born from these mothers to 2 years of age. In the first phase of this study, pregnant women were screened and enrolled between June 2014 and October 2014. Eligible mothers were not infected with HIV and were of all gravidities, with an estimated gestational age between 12 and 20 weeks, confirmed by ultrasound, and provided written informed consent. Complete entry criteria are provided (see S1 Study Protocol) and have been previously described [28]. In the second phase of this study, children were born between October 2014 and May 2015 and followed through 2 years of age, with the last participant followed through May 2017.

**Study design and randomization**

This was a double-blinded RCT of pregnant women not infected with HIV and the children born to them. Women and their unborn child(ren) were randomized to one of five treatment arms, including both the intervention for the woman during pregnancy and her unborn child(ren) during infancy, in a 2:1:1:1:1 randomization scheme, as follows: (1) women IPTp-SP8w, children DP every 12 weeks; (2) women IPTp-DP8w, children DP every 12 weeks; (3) women IPTp-DP8w, children DP every 4 weeks; (4) women IPTp-DP4w, children DP every 12 weeks; and (5) women IPTp-DP4w, children DP every 4 weeks. To compare the malaria risk among infants whose mothers were randomized to different IPTp regimens, the prespecified protocol-defined study population included only mother/infant pairs in one of the three study arms randomized to receive DP every 12 weeks during infancy, because we hypothesized that children randomized to receive DP every 4 weeks in infancy would be nearly completely protected against malaria in infancy [29].

A randomization list using permuted blocks of 6 or 12 was computer generated by a member of the study not directly involved in patient care. Study participants were randomized to their assigned treatment group at enrolment using premade, consecutively numbered, sealed envelopes. Non-singleton births from the same mother were assigned to the same intervention. Study pharmacists not otherwise involved in the study were responsible for treatment allocation and the preparation of study drugs.

**Study drugs**

In pregnancy, each treatment with SP (Kamsidar, Kampala Pharmaceutical Industries, 500/25 mg tablets) consisted of 3 tablets given as a single dose. Each treatment with DP in pregnancy
(Duo-Cotexin, Holley-Cotec, Beijing, China, 40 mg/320 mg tablets) consisted of 3 tablets given once a day for 3 consecutive days. Participants allocated IPTp-SP8w or IPTp-DP8w received active study drugs at 20, 28, and 36 weeks gestational age. Participants allocated IPTp-DP4w received active study drugs starting at 16 or 20 weeks gestational age. Placebos of SP and DP were used such that every 4 weeks participants received the same number of pills, with the same appearance.

Each treatment with DP in childhood consisted of half-strength tablets given once a day for 3 consecutive days (Duo-Cotexin, Holley-Cotec, Beijing, China, 20 mg/160 mg tablets), according to weight-based guidelines (see S1 Study Protocol). Infants randomized to receive DP every 12 weeks received placebo mimicking the dosing of DP every 4 weeks when they were not receiving study drug. The first day of each dose was directly observed in the clinic by study nurses, who had the flexibility to administer either intact or crushed tablets to the infants. Compliance with day 2 and day 3 dosing administered at home was assessed at the following monthly routine visit and was reported to be >99%.

Study procedures
At enrolment, women received an LLIN and underwent a standardized examination. Pregnant women and their children received all of their medical care at a study clinic open every day. Study procedures for pregnant women have previously been described, with details available in S1 Study Protocol [8]. Briefly, during pregnancy, routine visits were conducted every 4 weeks, including collection of dried blood spots (DBS) for molecular testing, and women were encouraged to deliver at the hospital adjacent to the study clinic. At delivery, a standardized assessment was completed, including evaluation of birth weight and collection of biological specimens, including maternal blood, placental tissue, placental blood, and cord blood.

Following delivery, children were followed through 24 months of age and encouraged to come to the study clinic any time they were ill. Those who presented with a documented fever ( tympanic temperature $\geq 38.0 ^\circ C$) or history of fever in the previous 24 hours had blood collected for a thick blood smear. If the smear was positive, the patient was diagnosed with malaria and treated with AL. If the thick blood smear was negative, the patient was managed for a non-malarial febrile illness by study physicians. Episodes of uncomplicated malaria in children <4 months of age or weighing <5 kg, as well as episodes of complicated malaria and treatment failures within 14 days, were treated with either quinine or artesunate according to national malaria treatment guidelines. Routine visits were conducted every 4 weeks in children, including thick blood smears to assess for parasitemia by microscopy, collection of DBS for molecular testing, and collection of plasma by fingerprick for assessment of piperaquine (PQ) levels. Phlebotomy for routine laboratory tests, including complete blood count (CBC), was performed every 16 weeks. Adverse events were assessed and graded according to standardized criteria at every visit to the study clinic [30].

Clinical laboratory procedures
Blood smears were stained with 2% Giemsa and read by experienced laboratory technologists. A blood smear was considered negative when the examination of 100 high-power fields did not reveal asexual parasites. For quality control, all slides were read by a second microscopist, and a third reviewer would settle any discrepant readings. DBS were tested for the presence of malaria parasites using a loop-mediated isothermal amplification (LAMP) kit (Eiken Chemical, Japan).
Antibody measurements

IgG responses to 19 parasite surface antigens were measured in maternal and cord blood collected at delivery, including circumsporozoite protein (CSP), erythrocyte binding antigen (EBA) 140 region III-V (RIII-V), EBA175 RIII-V [31,32], EBA181 RIII-V, Early transcribed membrane protein (Etramp) 4, Etramp 5, gametocyte exported protein (GEXP18), H103/merozoite surface protein (MSP) 11, Heat shock protein 40 (HSP40), Plasmodium exported protein (Hyp2) [33], MSP 2 (Ch150/9 and Dd2 alleles) [34], Apical membrane antigen 1 (AMA1) [31,32,35], glutamate rich protein (GLURP-R2)[36], MSP1-19 [31,32,37], Schizont egress antigen (SEA)-1 [38], Reticulocyte-binding protein homologue (Rh)2, Rh4.2, and skeleton-binding protein 1 (SBP1). Glutathione S-transferase (GST) and Tetanus toxoid were used as controls. Luminex magnetic microsphere conjugation was performed by standard methods [39]. Fifty microliters thawed plasma (1/1,000 dilution) were coincubated with microsphere mixtures on a 96-well plate for 90 minutes, washed, then stained with 50 uL of 1/200 R-Phycerythrin-conjugated AffiniPure F(ab')2 Goat anti-human IgG (Jackson Immuno Research Laboratories) secondary antibody. Samples were then suspended in 100 uL PBS and read by the Luminex MAGPIX system. Positive control samples from individuals (n = 20) with known antibodies to these antigens were included on each plate. Standard curves were generated through serial dilutions of the positive control pool. Antibody levels, expressed in arbitrary units (AUs), were obtained by regressing raw MFI onto the standard curve for each antigen present on every plate and results log transformed [40].

PQ pharmacokinetic sample collection and quantitation

Children provided capillary blood samples at 3 consecutive routine visits performed every 4 weeks after they received the 8, 32, 56, and 92 week doses of DP in infancy. Pharmacokinetic samples (n = 1,505) were centrifuged within 60 minutes at 2,000g for 10 minutes, and plasma was stored at −80˚C prior to being processed for PQ quantitation. PQ concentrations were determined using high performance liquid chromatography tandem mass spectrometry, as described [41], with modifications to lower the calibration range to 0.5–50 ng/mL and a new calibration range of 10–1,000 ng/mL. The lower limit of quantification (LLOQ) was 0.5 ng/mL and the coefficient of variance was <10% for all quality control concentrations.

Study end points

The primary outcome was the incidence of malaria from birth to 24 months of age. Treatments for malaria within 14 days of a prior episode were not considered incident events. Secondary outcomes included time to malaria from birth and time to parasitemia following receipt of each dose of DP; the incidence of complicated malaria; the incidence of hospitalizations/ deaths; the incidence of non-malarial febrile illness (presentation within 14 days of a prior episode were not considered incident events); and the prevalence of anemia (Hb < 11 g/dL) during infancy. Measures of safety included the incidence of adverse events from birth through 2 years of age. Post hoc, exploratory outcomes included the relative intensity of malarial antibodies measured at delivery (maternal and cord); and PQ levels measured 4, 8, and 12 weeks following receipt of DP. The primary exposure variable was maternal IPTp assignment.

Statistical analysis

To test the hypothesis that either IPTp-DP4w or IPTP-DP8w would be associated with a lower risk of malaria in infancy compared to SP, we assumed an incidence of malaria of 3–5 episodes
per person year (PPY) among children whose mothers were randomized to IPTp-SP8w based on prior data before the implementation of IRS. Assuming 5% lost to follow-up, we had 80% power to show a 22%–28% reduction in the incidence of malaria among infants whose mothers were randomized to either IPTp-DP4w or IPTp-DP8w (2-sided significance level = 0.05).

Data were double-entered and verified in Microsoft Access and statistical analysis performed using Stata, version 14. All analyses were done using a modified intention-to-treat approach, including all children born (excluding stillbirths) and randomized to DP every 12 weeks with evaluable person-time of follow-up. Any premature withdrawal from the study prior to 2 years of age was assumed to be random. Comparisons of simple proportions were made using the chi-squared or Fisher’s exact test. Comparisons of incidence measures were made using a negative binomial regression model. We assessed for significant interaction ($p < 0.10$) with the primary outcome and the following potential effect modifiers: sex of the infant, gestational age of the infant at birth, and maternal gravidity. Where significant effect modification was noted, results were reported from stratified analysis. The cumulative risk of developing malaria from birth was estimated using the Kaplan-Meier product limit formula, and associations with exposure variables assessed using a cox proportional hazards model. The cumulative risk of developing malaria parasitemia following receipt of each dose of DP in infancy was estimated using a multilevel mixed-effects parametric survival model, accounting for clustering within individuals and mothers (twin gestation). Comparisons of proportions with repeated measures were made using mixed effects logistic regression models. In all analyses, estimates accounted for maternal clustering (twin gestation). Estimates were adjusted for potential confounders (maternal age, gravidity, and maternal parasitemia status at enrolment); both unadjusted and adjusted results were reported in tables; adjusted estimates are presented in the text.

In post hoc analyses, comparisons of log-transformed antibody levels between groups were performed using the student $t$ test. For PQ measurements, relationships between mean population PQ concentrations, days since dosing, maternal randomization, and infant sex were assessed using generalized estimating equations with log link and robust standard errors accounting for repeated observations within individuals. Marginal estimates were produced using final models and shown graphically. In all analyses, $p < 0.05$ was considered statistically significant, without adjustment for multiple comparisons.

Results

Study participants and follow-up

Between June 2014 and October 2014, 386 pregnant women not infected with HIV and their unborn children were screened, and 300 were enrolled and randomized to one of five treatment arms defined by both maternal IPTp (SP8w, DP8w, or DP4w) and infant intermittent preventive treatment (IPT) (DP every 4 or 12 weeks beginning at 8 weeks of age, Fig 1). Among pregnant women/child pairs enrolled, 202 were randomized to receive DP every 12 weeks in infancy and included in this analysis. Of these, 106 women were randomized to IPTp-SP8w; 46 to IPTp-DP8w, and 50 to IPTp-DP4w. A total of 192 women (95.0%) were followed through delivery, and 4 women gave birth to twins. Of 194 live births, 191 children were followed for at least one day and included in the analyses. All children were born between October 2014 and May 2015.

Mean maternal age at enrolment was 22 years, 69% of women were enrolled at $\leq 16$ weeks gestational age, 37% were primigravida, and 57% had malaria parasites detected by LAMP. Baseline maternal characteristics were not significantly different between the 3 IPTp arms, except for age, with women randomized to IPTp-SP8w slightly younger than women
randomized to the other 2 treatment groups (Table 1). After initiation of IPTp, the incidence of malaria was significantly higher during pregnancy in mothers who received IPTp-SP8w (0.95 episodes PPY) compared to mothers who received IPTp-DP8w (0.23 episodes PPY, \( p = 0.004 \)) or IPTp-DP4w (0 episodes PPY, \( p < 0.001 \)). Similarly, parasite prevalence during pregnancy was significantly higher in mothers who received IPTp-SP8w compared to mothers who received IPTp-DP8w or IPTp-DP4w. The prevalence of placental malaria determined by

Table 1. Characteristics of mother-child pairs stratified by mother’s IPTp treatment arm.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mother’s IPTp treatment arm</th>
<th>( \text{SP8w (} n = 100) )</th>
<th>( \text{DP8w (} n = 44) )</th>
<th>( \text{DP4w (} n = 47) )</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristics of mothers at enrolment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>21.4 (3.6)</td>
<td>23.0 (4.1)</td>
<td>23.0 (3.8)</td>
<td></td>
</tr>
<tr>
<td>Weeks of gestation, ( n ) (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12–16 weeks</td>
<td>71 (71.0%)</td>
<td>29 (65.9%)</td>
<td>31 (66.0%)</td>
<td></td>
</tr>
<tr>
<td>&gt;16–20 weeks</td>
<td>29 (29.0%)</td>
<td>15 (34.1%)</td>
<td>16 (34.0%)</td>
<td></td>
</tr>
<tr>
<td>Mother’s gravidity, ( n ) (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>35 (35.0%)</td>
<td>10 (22.7%)</td>
<td>10 (21.3%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>33 (33.0%)</td>
<td>16 (36.4%)</td>
<td>16 (34.0%)</td>
<td></td>
</tr>
<tr>
<td>( \geq 3 )</td>
<td>32 (32.0%)</td>
<td>18 (40.9%)</td>
<td>21 (44.7%)</td>
<td></td>
</tr>
<tr>
<td>Household wealth index, ( n ) (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lowest third</td>
<td>37 (37.0%)</td>
<td>11 (25.0%)</td>
<td>15 (31.9%)</td>
<td></td>
</tr>
<tr>
<td>Middle third</td>
<td>29 (29.0%)</td>
<td>19 (43.2%)</td>
<td>15 (31.9%)</td>
<td></td>
</tr>
<tr>
<td>Highest third</td>
<td>34 (34.0%)</td>
<td>14 (31.8%)</td>
<td>17 (36.2%)</td>
<td></td>
</tr>
<tr>
<td>Detection of malaria parasites by LAMP(^a), ( n ) (%)</td>
<td>56 (56.0%)</td>
<td>19 (43.2%)</td>
<td>27 (57.5%)</td>
<td></td>
</tr>
<tr>
<td><strong>Characteristics of mothers during pregnancy after initiation of study drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incidence of malaria(^b)</td>
<td>0.95</td>
<td>0.23</td>
<td>0.004</td>
<td>0</td>
</tr>
<tr>
<td>Parasite prevalence(^c)</td>
<td>201/499 (40.3%)</td>
<td>24/203 (11.8%)</td>
<td>&lt;0.001</td>
<td>8/239 (3.4%)</td>
</tr>
<tr>
<td>Placental malaria by microscopy, ( n/N ) (%)</td>
<td>4/96 (4.2%)</td>
<td>1/44 (2.3%)</td>
<td>0.58</td>
<td>0/45 (0%)</td>
</tr>
<tr>
<td>Placental malaria by LAMP(^a), ( n/N ) (%)</td>
<td>19/96 (19.8%)</td>
<td>1/44 (2.3%)</td>
<td>0.006</td>
<td>0/45 (0%)</td>
</tr>
<tr>
<td>Placental malaria by histology, ( n/N ) (%)</td>
<td>49/97 (50.5%)</td>
<td>13/44 (29.6%)</td>
<td>0.02</td>
<td>10/45 (22.2%)</td>
</tr>
<tr>
<td><strong>Characteristics of children at birth</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female sex, ( n ) (%)</td>
<td>51 (51.0%)</td>
<td>24 (54.6%)</td>
<td>0.70</td>
<td>23 (48.9%)</td>
</tr>
<tr>
<td>Gestational age in weeks at birth, mean (SD)</td>
<td>39.3 (1.8)</td>
<td>39.1 (2.6)</td>
<td>0.54</td>
<td>40.0 (1.2)</td>
</tr>
<tr>
<td>Preterm births (&lt;37 weeks of gestation), ( n ) (%)</td>
<td>8 (8.0%)</td>
<td>5 (11.4%)</td>
<td>0.52</td>
<td>1 (2.1%)</td>
</tr>
<tr>
<td>Birth weight in grams, mean (SD)</td>
<td>2,967 (447)</td>
<td>2,928 (532)</td>
<td>0.65</td>
<td>3,024 (339)</td>
</tr>
<tr>
<td>Low birth weight (&lt;2,500 gm), ( n ) (%)</td>
<td>13 (13.0%)</td>
<td>6 (13.6%)</td>
<td>0.92</td>
<td>2 (4.3%)</td>
</tr>
</tbody>
</table>

\(^a\) Reference group.
\(^b\) Episodes of malaria per person year at risk.
\(^c\) Proportion of routine blood samples positive for malaria parasites by LAMP.

Abbreviations: DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; IPTp, intermittent preventive treatment of malaria in pregnancy; LAMP, loop-mediated isothermal amplification; SP8w, IPTp-SP given every 8 weeks.

https://doi.org/10.1371/journal.pmed.1002606.t001
LAMP or histopathology was significantly higher among women who received IPTp-SP8w compared to women who received IPTp with either IPTp-DP8w or IPTp-DP4w (Table 1).

Of 191 children born and followed, 98 (51.3%) were female, 14 (7.3%) were born preterm, and 21 (11%) were born with LBW (<2,500 g), and these characteristics were not significantly different based on maternal IPTp. Median gestation age at birth was slightly older for babies born to mothers who received IPTp-DP4w (median gestation age 40 weeks [35.7–41.6 weeks]) compared to those born to mothers who children whose mothers received IPTp-SP8w (median gestation age 39.3 weeks [31.7–42.0 weeks], p = 0.03, Table 1). Of 191 children followed, 164 (86%) completed follow-up through 2 years of age (Fig 1). When considering person-time of follow-up, 355.1 of 382 (93%) possible person years were observed.

Impact of IPTp with DP on burden of malaria in infancy

During 355.1 person years of follow-up, there were 105 incident episodes of malaria in infants, giving an overall incidence of 0.30 episodes PPY. Compared to children born to mothers who received IPTp-SP8w, the incidence of malaria during 24 months of follow-up was higher in children born to mothers who received IPTp-DP4w (adjusted incidence rate ratio [aIRR] 1.92; 95% CI 1.00–3.65, p = 0.049) and nonsignificantly higher in children born to mothers who received IPT-DP8w (aIRR 1.44; 95% CI, 0.68–3.05; p = 0.34, Table 2). However, we observed significant effect modification by infant sex. Female children born to mothers who received IPTp-DP4w had a greater than 4-fold apparently higher incidence of malaria (aIRR 4.39; 95% CI, 1.87–10.3; p = 0.001) compared to female children born to mothers who received IPTp-SP8w. Similarly, female children born to mothers who received IPTp-DP8w had a higher, but nonsignificant, risk of malaria compared to female children born to mothers who received IPTp-SP8w (aIRR 2.43; 95% CI, 0.85–6.97; p = 0.10). In contrast, there were no significant differences in the incidence of malaria among male children across the 3 IPTp treatment arms.

Table 2. Incidence of malaria though 24 months of age by mother’s IPTp treatment arm overall and stratified by infant sex.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Mother’s IPTp treatment arm</th>
<th>Number of children</th>
<th>Episodes of malaria</th>
<th>PY of observation</th>
<th>Incidence of malaria PY</th>
<th>IRR (95% CI)</th>
<th>p-value</th>
<th>aIRR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>SP8w</td>
<td>100</td>
<td>44</td>
<td>185.2</td>
<td>0.24</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>44</td>
<td>25</td>
<td>84.2</td>
<td>0.30</td>
<td>1.29</td>
<td>0.63–2.64</td>
<td>0.49</td>
<td>1.44</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>47</td>
<td>36</td>
<td>85.5</td>
<td>0.42</td>
<td>1.81</td>
<td>0.93–3.53</td>
<td>0.08</td>
<td>1.92</td>
</tr>
<tr>
<td>Female</td>
<td>SP8w</td>
<td>51</td>
<td>18</td>
<td>91.3</td>
<td>0.20</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>24</td>
<td>16</td>
<td>44.3</td>
<td>0.36</td>
<td>1.91</td>
<td>0.65–5.64</td>
<td>0.24</td>
<td>2.43</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>23</td>
<td>27</td>
<td>41.3</td>
<td>0.65</td>
<td>3.44</td>
<td>1.41–8.40</td>
<td>0.007</td>
<td>4.39</td>
</tr>
<tr>
<td>Male</td>
<td>SP8w</td>
<td>49</td>
<td>26</td>
<td>94.0</td>
<td>0.28</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>20</td>
<td>9</td>
<td>40.0</td>
<td>0.23</td>
<td>0.82</td>
<td>0.38–1.77</td>
<td>0.62</td>
<td>0.84</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>24</td>
<td>9</td>
<td>44.2</td>
<td>0.20</td>
<td>0.74</td>
<td>0.25–2.17</td>
<td>0.58</td>
<td>0.66</td>
</tr>
</tbody>
</table>

*Adjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.

*Interaction p-value between female sex and IPTp arm: 0.22 for IPTp-DP8w; 0.03 for IPTp-DP4w.

Abbreviations: aIRR, adjusted incidence rate ratio; DP4w, IPTp-DP given every 4 weeks; DP8w, IPTp-DP given every 8 weeks; SP8w, IPTp-SP given every 8 weeks; PPY, person per year; PY, person year; SP8w, IPTp-SP given every 8 weeks.

https://doi.org/10.1371/journal.pmed.1002606.t002
No significant effect modification was observed with maternal gravidity or gestational age at birth.

Children born to mothers who received IPTp-DP4w had a nonsignificantly increased hazard of developing a first episode of malaria during the first 2 years of life in comparison to children born to mothers who received IPTp-SP8w (adjusted hazard ratio [aHR] 1.76, 95% CI 0.93–3.35, p = 0.08), but we again observed significant interaction with infant sex. Female infants whose mothers received IPTp-DP4w had a 3-fold apparently increased hazard of developing malaria compared to infants born to mothers who received IPTp-SP8w (aHR 3.40; 95% CI 1.55–7.96; p = 0.002, Table 3). Female children born to mothers who received IPTp-DP8w also had a higher, but nonsignificant, increased risk of malaria compared to those whose mothers received IPTp-SP8w; no significant associations were observed among male children across the 3 IPTp treatment arms (Table 3). These data do not support our original hypothesis that preventing malaria exposure in utero with DP leads to a reduced incidence of malaria in childhood; in contrast, in this setting it may be associated with an increased incidence of malaria in females.

Given these differences, we assessed whether the incidence of malaria was different between male and female children. Overall, female children had a nonsignificantly increased incidence of malaria compared to males (aIrr 1.43, 95% CI 0.82–2.50, p = 0.21), but this effect was modified by maternal IPTp. Female children whose mothers were randomized to IPTp-DP4w had a >3-fold apparently increased risk of malaria compared to males (aIrr 3.34, 95% CI 1.08–10.26, p = 0.04). However, there were no significant sex-specific differences among children whose mothers were randomized to IPTp-SP8w (aIrr 0.72, 95% CI 0.31–1.67 comparing females to males) or IPTp-DP8w (aIrr 1.66, 95% CI 0.59–4.67 comparing females to males). These data suggest that, in this setting, female infants appear to have an increased risk of malaria in infancy compared to males, but only among those whose mothers received IPTp-DP4w.

### Table 3. Time to first episode of malaria by mother’s IPTp treatment arm overall and stratified by infant sex.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Mother’s IPTp treatment arm</th>
<th>Number of children</th>
<th>Number with any malaria</th>
<th>Cumulative risk of any malaria (95% CI)</th>
<th>HR (95% CI)</th>
<th>p-value</th>
<th>aHR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allb</td>
<td>SP8w</td>
<td>100</td>
<td>26</td>
<td>28.4% (20.2%–38.3%)</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>44</td>
<td>13</td>
<td>30.8% (19.2%–47.1%)</td>
<td>1.15</td>
<td>0.68</td>
<td>1.36 (0.67–2.76)</td>
<td>0.40</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>47</td>
<td>16</td>
<td>37.0% (24.6%–53.2%)</td>
<td>1.54</td>
<td>0.18</td>
<td>1.76 (0.93–3.35)</td>
<td>0.08</td>
</tr>
<tr>
<td>Female</td>
<td>SP8w</td>
<td>51</td>
<td>11</td>
<td>24.3% (14.3%–39.7%)</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>24</td>
<td>5</td>
<td>22.4% (10.0%–45.7%)</td>
<td>0.97</td>
<td>0.96</td>
<td>1.21 (0.39–3.69)</td>
<td>0.74</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>23</td>
<td>11</td>
<td>52.4% (33.3%–74.3%)</td>
<td>2.97</td>
<td>0.01</td>
<td>3.40 (1.55–7.96)</td>
<td>0.002</td>
</tr>
<tr>
<td>Male</td>
<td>SP8w</td>
<td>49</td>
<td>15</td>
<td>32.3% (20.9%–47.8%)</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>20</td>
<td>8</td>
<td>40.0% (22.4%–64.3%)</td>
<td>1.35</td>
<td>0.49</td>
<td>1.51 (0.59–3.88)</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>24</td>
<td>5</td>
<td>22.7% (10.1%–46.3%)</td>
<td>0.71</td>
<td>0.51</td>
<td>0.82 (0.29–2.32)</td>
<td>0.71</td>
</tr>
</tbody>
</table>

*Adjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.

*bInteraction p-value between female sex and IPTp arm: 0.63 for IPTp-DP8w; 0.03 for IPTp-DP4w.

Abbreviations: aHR, adjusted hazard ratio; DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; HR, hazard ratio; IPTp, intermittent preventive treatment of malaria in pregnancy; LAMP, loop-mediated isothermal amplification; SP8w, IPTp-SP given every 8 weeks.

https://doi.org/10.1371/journal.pmed.1002606.t003
After observing an apparently higher risk of clinical malaria among female infants whose mothers received IPTp-DP4w compared to those whose mothers received IPTp-SP8w, we next sought to determine whether these infants were at an increased risk of *P. falciparum* infection in infancy versus an increased risk of symptoms if infected. As children followed in this study received curative IPT with DP every 12 weeks beginning at 8 weeks of age, and had both passive and active surveillance for *P. falciparum* infection, we assessed time to parasitemia following each dose of DP in infancy. Overall, children born to mothers who received IPTp-DP4w had an increased hazard of parasitemia following receipt of DP in infancy compared to children born to mothers who received IPTp-SP8w (aHR 2.02, 95% CI 1.08–3.79, \( p = 0.03 \), Fig 2A, Table 4), but we again observed significant interaction with infant sex. Female infants whose mothers had received IPTp-DP4w had a more than 5-fold apparently increased hazard of developing parasitemia following receipt of DP in infancy than children born to mothers who received IPTp-SP8w (aHR 5.02; 95% CI, 1.90–13.2, \( p = 0.001 \), Fig 2B, Table 4). There was no significant difference in the hazard of developing parasitemia among male children born to mothers who received IPTp-DP4w or IPTp-SP8w compared to male children born to mothers who received IPTp-SP8w (Table 4, Fig 2C). Prior to first receipt of DP at 8 weeks of age, parasitemia was rare: 1/182 (0.55%) were LAMP positive at week 4, and 3/183 (1.64%) were...
microscopy or LAMP positive at 8 weeks of age. All 4 children with parasitemia at or before 8 weeks of age were born to mothers who received IPTp-SP8w, and none of these episodes were symptomatic. These data suggest that the increased incidence of malaria among female infants whose mothers received IPTp-DP4w is directly related to an increased risk of blood stage \textit{P. falciparum} infection following receipt of DP in infancy.

Secondary clinical and safety outcomes

During 2 years of follow-up, there were 9 episodes of complicated malaria: 4 among the 100 infants whose mothers received IPTp-SP8w (0.02 episodes PPY), 2 among 44 infants whose mothers received IPTp-DP8w (0.02 episodes PPY), and 3 among 47 infants whose mothers received IPTp-DP4w (0.04 episodes PPY). The risk of complicated malaria did not significantly differ between IPTp groups, nor between infant sex (5 episodes in males, 4 in females). Of the 9 episodes, 8 occurred between 12 and 24 months of age, 6 of 9 represented the child’s first episode of malaria and were associated with 1–2 convulsive episodes, and no episodes of cerebral malaria or severe anemia were observed. There were 3 deaths among infants included in this study. None of the deaths were due to malaria. Overall, there were 18 hospitalizations or deaths, with no significant difference in the number of hospitalization or deaths between IPTp treatment arms (Table 5). Children whose mothers received IPTp-DP4w or IPTp-DP8w had a nonsignificantly lower risk of anemia (hemoglobin <11 g/dL) compared to children whose mothers received IPTp-SP8w. Children born to mothers who received IPTp-DP4w or IPTp-DP8w also had a nonsignificantly lower incidence of non-malarial febrile illnesses compared to children born to mothers who received IPTp-SP8w (Table 5). These results are consistent with one other observational birth cohort, which found that malaria in pregnancy was associated with a higher risk of non-malarial febrile illness [42]. There were no significant
differences in the incidence of adverse events of any severity, grade 3–4 adverse events, or serious adverse events (S1 Table). No adverse events were thought to be related to study drugs.

### Impact of IPTp with DP on antibody responses in infancy

Given the apparent sex-specific differences in malaria risk observed among infants whose mothers were randomized to different IPTp regimens, we then performed exploratory analyses to evaluate potential mechanistic explanations. As passive transfer of protective antibodies from the mother to the newborn may lead to a reduced risk of malaria early in life [37,43], we first assessed the impact of maternal IPTp regimens on malaria-specific IgG antibody levels in maternal and infant cord blood using a high-sensitivity Luminex-based, multiplex fluorescent bead-based assay. Although antibody levels to several antigens were significantly lower at delivery among mothers who received IPTp-DP4w in comparison to mothers who received IPTp-SP, IgG antibody levels measured in infant cord blood were similar between groups for all antigens (Fig 3). Furthermore, no significant sex-specific differences in antibody levels were observed. Therefore, the increased malaria risk observed among female infants whose mothers received IPTp-DP4w did not appear to be due to decreased malaria-specific antibody levels secondary to suppression of infection.

### Exposure to DP during pregnancy and PQ levels in infancy

Because PQ trough levels are strongly predictive of malaria risk among children receiving IPT with DP [29], we next assessed whether there were sex-specific differences in PQ levels in infancy and whether in utero exposure to DP alters these PQ levels. Capillary PQ levels were measured 28, 56, and 84 days post the 8, 32, 56, and 92 week doses of DP in infancy (n = 1,505 measurements). Female children whose mothers were randomized to IPTp-DP4w had 19% lower mean PQ levels during infancy compared to female children whose mothers received IPTp-SP8w (coef 0.81, 95% CI 0.65–1.00, \( p = 0.048 \)). In contrast, male children whose mothers

---

**Table 5. Secondary outcomes by mother’s IPTp regimen.**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Sex</th>
<th>Mother’s IPTp treatment arm</th>
<th>Episodes or prevalence</th>
<th>PY of observation</th>
<th>Incidence PPY</th>
<th>IRR or OR (95% CI)</th>
<th>( p )-value</th>
<th>aIRR* or aOR* (95% CI)</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalizations or deaths</td>
<td>All</td>
<td>SP8w</td>
<td>9</td>
<td>185.2</td>
<td>0.05</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>2</td>
<td>84.2</td>
<td>0.02</td>
<td>0.49</td>
<td>(0.11–2.18)</td>
<td>0.35</td>
<td>0.52</td>
<td>(0.11–2.47)</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>7</td>
<td>85.5</td>
<td>0.08</td>
<td>1.69</td>
<td>(0.43–4.42)</td>
<td>0.29</td>
<td>1.76</td>
<td>(0.64–4.90)</td>
</tr>
<tr>
<td>Non-malarial febrile illnesses</td>
<td>All</td>
<td>SP8w</td>
<td>769</td>
<td>185.2</td>
<td>4.15</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>302</td>
<td>84.2</td>
<td>3.59</td>
<td>0.85</td>
<td>(0.69–1.06)</td>
<td>0.16</td>
<td>0.86</td>
<td>(0.69–1.07)</td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>292</td>
<td>85.5</td>
<td>3.42</td>
<td>0.82</td>
<td>(0.67–1.02)</td>
<td>0.07</td>
<td>0.82</td>
<td>(0.66–1.02)</td>
</tr>
<tr>
<td>Anemia (^b)</td>
<td>All</td>
<td>SP8w</td>
<td>295/619 (47.7%)</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
<td>reference</td>
</tr>
<tr>
<td></td>
<td>DP8w</td>
<td>126/279 (45.2%)</td>
<td>0.85</td>
<td>(0.51–1.44)</td>
<td>0.55</td>
<td>0.91</td>
<td>(0.54–1.54)</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DP4w</td>
<td>119/285 (41.8%)</td>
<td>0.73</td>
<td>(0.44–1.22)</td>
<td>0.24</td>
<td>0.78</td>
<td>(0.46–1.29)</td>
<td>0.33</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Adjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.

\(^b\)Hemoglobin <11 gm/dL at the time of routine visits conducted every 16 weeks.

Abbreviations: aIRR, adjusted incidence rate ratio; aOR, adjusted odds ratio (for anemia prevalence models); DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; IPTp, intermittent preventive treatment of malaria in pregnancy; IRR, incidence rate ratio; LAMP, loop-mediated isothermal amplification; OR, odds ratio; PY, person year; PPY, per person year; SP8w, IPTp-SP given every 8 weeks.

https://doi.org/10.1371/journal.pmed.1002606.t005
were randomized to IPTp-DP4w had 17% higher mean PQ levels during infancy compared to males whose mothers received IPTp-SP8w, although not significantly so (coef 1.17, 95% CI 0.92–1.50, \( p = 0.21 \)). In addition, female children whose mothers were randomized to IPTp-DP4w had 28% lower mean PQ levels post-dose than male children (coef 0.72, 95% CI 0.57–0.91, \( p = 0.006 \), Fig 4C). However, there were no significant sex-specific differences among children whose mothers were randomized to IPTp-SP8w (coef 1.07, 95% CI 0.86–1.32, \( p = 0.57 \), Fig 4A) or IPTp-DP8w (coef 1.09, 95% CI 0.97–1.38, \( p = 0.44 \), Fig 4B). Together, these data suggest that consistent in utero exposure to DP may lead to sex-specific differences in PQ metabolism in infancy, with lower PQ levels following administration among female infants.

**Discussion**

In many parts of Africa, the current standard of care for IPTp—SP given at routine antenatal visits—remains inadequate to prevent malaria in pregnancy. DP has emerged as a promising alternative to IPTp-SP in settings with high SP resistance [7,28], but an important consideration is what impact IPTp-DP has on the risk of malaria during infancy. In contrast to our original hypothesis, we found that children born to mothers given IPTp-DP did not have a lower risk of malaria in infancy than children born to mothers given IPTp-SP. Rather, in a setting where children were given IPT with DP every 12 weeks during infancy, IPTp-DP4w was associated with a higher risk of malaria and *P. falciparum* infection in infancy—but only in female infants. Although levels of malaria-specific antibodies in cord blood did not significantly differ between IPTp groups and/or sex, female children whose mothers were randomized to IPTp-DP4w had significantly lower PQ levels during infancy compared to male children, suggesting that consistent in utero exposure to DP may lead to sex-specific differences in PQ metabolism in infancy.

Several epidemiologic and immunologic studies have previously suggested that in utero exposure to malaria may significantly increase a child’s subsequent risk of malaria [9–14], potentially by leading to immunologic tolerance of the parasite [11]. However, this has not been a universal observation, with some studies finding no significant association between in utero malaria exposure and subsequent malaria risk [16–18], and others reporting significant effect modification by maternal gravidity [14]. Importantly, as these were all observational studies, it is entirely possible that these associations are the result of confounding (i.e., mothers with malaria in pregnancy may live in foci of higher malaria transmission, and, therefore, their children are more likely to be exposed to infected mosquitoes in infancy) [19]. Although interventional studies following children born to mothers randomized to different IPTp regimens might more causally assess this question, few such RCTs have been performed. In the 4 studies, to our knowledge, in which pregnant women were randomized to different IPTp regimens and children followed during infancy, and exposure to infected mosquitoes can therefore be presumed to be equal between groups of children following birth, the incidence of malaria was not significantly different between groups [12,18,20,21]. However, in 3 of these 4 studies, the
Fig 4. Mean PQ levels measured 28, 56, and 84 days posttreatment among children whose mothers were randomized to IPTp-SP8w (A), IPTp-DP8w (B), and IPTp-DP4w (C). Marginal estimates obtained using generalized estimating observations with log link and robust standard errors, accounting for repeated measurements in
experimental group (IPTp-SP + LLIN, IPTp with mefloquine, or ISTp with AL) did not significantly reduce the burden of placental malaria in comparison to controls (LLIN alone or IPTp-SP for the latter 2 trials, respectively) [22–24]. In the older, placebo-controlled trial of IPTp with mefloquine in Thailand, mefloquine significantly reduced the burden of malaria in pregnancy in comparison to placebo. However, the child’s age at first malaria episode was assessed only through interview of the mother, and malaria blood smears were only performed at 1 week, 2 months, and 9 months of age [20].

In our placebo-controlled, randomized controlled study, IPTp-DP4w significantly reduced the burden of malaria infection during pregnancy and at delivery, offering an ideal opportunity to determine what impact reducing exposure to malaria in pregnancy might have on the risk of malaria in infancy. Children were followed through 2 years of age with both active and passive surveillance, allowing for precise determination of malaria metrics in infancy. Our study differed from the previously described studies above in that children born to mothers randomized to different IPTp interventions were themselves given IPT with DP every 12 weeks during infancy. In this setting, where the overall incidence of malaria in infancy was relatively low (0.3 episodes PPY), female infants whose mothers were randomized to IPTp-DP4w had an apparently 4-fold increased incidence of malaria and hazard of parasitemia following receipt of DP in infancy compared to female infants whose mothers were randomized to IPTp-SP8w. Female infants whose mothers were randomized to IPTp-DP8w also had nonsignificantly increased incidence of malaria and hazard of parasitemia. Importantly, no differences were observed among male children, adding to a growing literature suggesting sex-based differences in susceptibility to infectious diseases and vaccinations [44–47].

What might explain these sex-specific differences in malaria risk among children whose mothers were given different IPTp regimens? Several potential mechanisms for sex-based differences in susceptibility to infectious diseases have been described, including genetic differences attributable to X chromosome inactivation [48], sex-dependent differences in glucocorticoid receptor expression and fetal-placental responsivity to cortisol [49], and sex-specific differences in neonatal and infant immune responses [46,50]. In this study, we measured antibody levels to a broad array of antimalarial antigens in cord blood, given prior literature suggesting that passive transfer of protective antibodies from the mother to the newborn may mediate protection from malaria in the first 6–12 months of life [37,43,51]. Although we did not observe significant differences in antibody levels between IPTp groups or between females and males, our assay was limited to the antigens screened and did not include assessment of antibody functionality.

In our setting, an increased malaria risk among children was only observed among female infants whose mothers were randomized to IPTp with DP4w. Furthermore, we observed lower PQ concentrations among female infants whose mothers were randomized to IPTp with DP4w. Although pharmacokinetic studies of DP have not observed sex-specific differences in PQ levels to date, one possible explanation for these findings is that PQ exposure in utero or as a neonate may result in clinically important, sex-specific differences in PQ metabolism. PQ has been found in breast milk [52], and although transplacental transfer has not been documented for PQ, related aminoquinolones chloroquine [53] and mefloquine [54] are known to cross the placenta. PQ is metabolized by cytochrome P450 (CYP) 3A4/2C8 in adults [55], but enzymes responsible for PQ metabolism in infancy are not known. During the first 2 years of life, fetal CYP3A7 is gradually replaced by CYP3A4 [56], and potential explanations for sex-

---

children. *p < 0.05. **p < 0.01. DP, dihydroartemisinin-piperaquine; IPTp, intermittent preventive treatment of malaria in pregnancy; DP4w, IPTp-DP given every 4 weeks; DP8w, IPTp-DP given every 8 weeks; SP8w, IPTp-SP given every 8 weeks; PQ, piperaquine; SP, sulfadoxine-pyrimethamine.

https://doi.org/10.1371/journal.pmed.1002606.g004
specific differences in PQ metabolism include sex-specific induction of fetal hepatic enzymes such as CYP3A7, which has been observed among female fetuses exposed to smoke [57], or accelerated maturation of adult CYP3A4, which may preferentially affect females who may have higher concentrations of CYP3A4 [58]. Further study will be needed to characterize the etiology of the lower PQ concentrations identified in female infants with mothers who received more frequent DP dosing.

Although we report findings from a randomized clinical trial, there were several important limitations. Our results suggesting an increased risk of malaria in female infants whose mothers were randomized to IPTp-DP must be interpreted with caution, as small sample size (especially when stratified by infant sex) may lend to spurious results. Furthermore, as children in this study all received DP every 12 weeks in infancy, we are unable to determine what impact maternal IPTp-DP has on infants who do not receive any IPT in infancy, which may be a more generalizable population across Africa. We are currently conducting a larger study comparing IPTp-DP with IPTp-SP among 782 mother-child pairs, in which children will be followed for 1 year following birth and not receive IPT in infancy. Finally, although suggestive of a potential mechanism of increased risk, our PQ data are speculative and require more formal pharmacokinetic/pharmacodynamic modelling, which is in progress.

In conclusion, our results show that effective prevention of in utero exposure to malaria with IPTp-DP does not result in a reduced risk of malaria in infants in comparison to IPT-SP. In contrast, in a setting where children were given IPT with DP every 12 weeks during infancy, IPTp-DP was associated with an increased risk of malaria in infancy, but only in female children. Future studies are needed to better understand the biological mechanisms of in utero drug exposure on drug metabolism and how this may affect the dosing of antimalarial drugs for treatment and prevention during infancy.

Supporting information

S1 CONSORT Checklist.
(DOC)

S1 Study Protocol.
(DOC)

S1 Table. Measures of safety and adverse events.
(DOCX)

S1 Statistical Analysis Plan.
(DOCX)

S1 Analysis Timeline.
(XLSX)

Acknowledgments

We are grateful to all the parents and guardians for kindly giving their consent and to the study participants for their cooperation. We thank all the members of the study teams for their dedication and excellent work.

Author Contributions

Conceptualization: Prasanna Jagannathan, Abel Kakuru, Mary Prahl, Margaret E. Feeney, Diane V. Havlir, Moses R. Kamya, Grant Dorsey.
**Data curation:** Prasanna Jagannathan, Jaffer Okiring, Mary K. Muhindo, Bishop Opira, Edwin D. Charlebois, Grant Dorsey.

**Formal analysis:** Prasanna Jagannathan, Abel Kakuru, Erika Wallender, Edwin D. Charlebois, Grant Dorsey.

**Funding acquisition:** Margaret E. Feeney, Diane V. Havlir, Moses R. Kamya, Grant Dorsey.

**Investigation:** Mary K. Muhindo, Paul Natureeba, Miriam Nakalembe, Bishop Opira, Peter Olwoch, Felistas Nankya, Isaac Ssewanyana, Tamara D. Clark, Isabel Rodriguez-Barraquer, Erika Wallender, Grant Dorsey.

**Methodology:** Mary K. Muhindo, Paul Natureeba, Felistas Nankya, Isaac Ssewanyana, Kevin Tetteh, Chris Drakeley, James Beeson, Linda Reiling, Isabel Rodriguez-Barraquer, Bryan Greenhouse, Francesca Aweeeka, Grant Dorsey.

**Project administration:** Bishop Opira, Tamara D. Clark, Moses R. Kamya.

**Resources:** Kevin Tetteh, Chris Drakeley, James Beeson, Linda Reiling, Francesca Aweeeka, Margaret E. Feeney.

**Software:** Jaffer Okiring.

**Supervision:** Prasanna Jagannathan, Abel Kakuru, Miriam Nakalembe, Peter Olwoch, Isaac Ssewanyana, Kevin Tetteh, Tamara D. Clark, Bryan Greenhouse, Mary Prahl, Edwin D. Charlebois, Diane V. Havlir, Moses R. Kamya, Grant Dorsey.

**Writing – original draft:** Prasanna Jagannathan, Abel Kakuru.

**Writing – review & editing:** Prasanna Jagannathan, Abel Kakuru, Jaffer Okiring, Mary K. Muhindo, Paul Natureeba, Miriam Nakalembe, Bishop Opira, Peter Olwoch, Felistas Nankya, Isaac Ssewanyana, Kevin Tetteh, Tamara D. Clark, Bryan Greenhouse, Erika Wallender, Francesca Aweeeka, Mary Prahl, Edwin D. Charlebois, Margaret E. Feeney, Diane V. Havlir, Moses R. Kamya, Grant Dorsey.

**References**


